Insider Selling: Tempus AI (NASDAQ:TEM) CEO Sells $6,577,839.51 in Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 132,591 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total value of $6,577,839.51. Following the completion of the sale, the chief executive officer directly owned 2,098,130 shares of the company’s stock, valued at approximately $104,088,229.30. This trade represents a 5.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Tempus AI Stock Performance

Shares of TEM stock traded up $5.40 during midday trading on Thursday, hitting $66.65. The company had a trading volume of 20,103,049 shares, compared to its average volume of 5,600,288. The company’s 50 day simple moving average is $52.44 and its 200 day simple moving average is $51.21. Tempus AI, Inc. has a 52-week low of $40.77 and a 52-week high of $104.32. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16. The stock has a market cap of $12.03 billion, a price-to-earnings ratio of -46.28 and a beta of 3.58.

Tempus AI (NASDAQ:TEM) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.10. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The company had revenue of $382.49 million for the quarter, compared to analysts’ expectations of $379.69 million. During the same period in the previous year, the company posted ($0.22) EPS. Tempus AI’s revenue was up 21.6% compared to the same quarter last year. Research analysts anticipate that Tempus AI, Inc. will post -1.38 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

TEM has been the subject of a number of research analyst reports. Piper Sandler cut their price target on shares of Tempus AI from $58.00 to $56.00 and set a “neutral” rating for the company in a report on Tuesday, August 4th. Guggenheim upped their target price on shares of Tempus AI from $60.00 to $65.00 and gave the stock a “buy” rating in a research report on Thursday, July 16th. TD Cowen reaffirmed a “buy” rating on shares of Tempus AI in a report on Wednesday, July 15th. Wolfe Research assumed coverage on shares of Tempus AI in a research report on Tuesday, June 2nd. They set a “peer perform” rating for the company. Finally, Wall Street Zen raised Tempus AI from a “sell” rating to a “hold” rating in a research note on Saturday, July 25th. Nine equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $65.69.

Key Stories Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: BTIG raised its price target to $80 from $70 and maintained a “Buy” rating, implying roughly 20% upside from the referenced price. The upgrade provided a direct catalyst for investor buying. BTIG raises Tempus AI price target
• Positive Sentiment: Investor attention is focusing on Tempus AI’s approximately $1.5 billion stock-based agreement to acquire Personalis. The deal is increasingly viewed as strategically valuable because Personalis’ genomic data and cancer-testing capabilities could strengthen Tempus’ precision-medicine and drug-development platform. Tempus AI biotech deal attracts investor attention
• Positive Sentiment: Moderna’s reported cancer-vaccine progress, alongside developments involving Merck, has encouraged investors to believe Tempus’ Personalis acquisition could benefit from increased demand for genomic data and personalized cancer treatment. The connection is indirect, but it has improved sentiment around Tempus’ strategic positioning. Tempus AI stock rises after Merck-Moderna cancer vaccine breakthrough
• Positive Sentiment: The rally was accompanied by unusually high options activity, with investors buying 40,671 call contracts—about 57% above average daily call volume—signaling increased bullish speculation and potentially reinforcing upward momentum.
• Neutral Sentiment: Technical factors also contributed: TEM moved above key moving averages, while coverage characterized the move as a possible short squeeze. These conditions can accelerate gains but may also increase volatility. Tempus AI stock technical rally

Institutional Investors Weigh In On Tempus AI

Several institutional investors and hedge funds have recently made changes to their positions in the business. Pictet Asset Management Holding SA grew its position in shares of Tempus AI by 291.3% in the fourth quarter. Pictet Asset Management Holding SA now owns 48,488 shares of the company’s stock valued at $2,948,000 after purchasing an additional 36,096 shares during the last quarter. Bogart Wealth LLC raised its position in shares of Tempus AI by 365,087.5% during the 4th quarter. Bogart Wealth LLC now owns 58,430 shares of the company’s stock worth $3,450,000 after purchasing an additional 58,414 shares during the last quarter. Eagle Health Investments LP acquired a new position in shares of Tempus AI during the 1st quarter worth approximately $11,588,000. Alethea Capital Management LLC purchased a new stake in Tempus AI in the 4th quarter valued at approximately $1,863,000. Finally, Hussman Strategic Advisors Inc. lifted its stake in Tempus AI by 100.0% in the 4th quarter. Hussman Strategic Advisors Inc. now owns 42,000 shares of the company’s stock valued at $2,480,000 after buying an additional 21,000 shares in the last quarter. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.